vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and AMERISAFE INC (AMSF). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $80.1M, roughly 1.7× AMERISAFE INC). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 10.2%, a 25.3% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 10.3%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 2.8%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
AMERISAFE Inc. is a specialty insurance provider that focuses exclusively on workers' compensation coverage for small and mid-sized businesses in high-hazard industries including construction, logging, trucking, and manufacturing. It operates across 49 U.S. states, offering tailored insurance policies paired with targeted risk management support for clients.
ADMA vs AMSF — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $80.1M |
| Net Profit | $49.4M | $8.1M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | — |
| Net Margin | 35.5% | 10.2% |
| Revenue YoY | 18.4% | 10.3% |
| Net Profit YoY | -55.9% | -9.0% |
| EPS (diluted) | $0.20 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $80.1M | ||
| Q4 25 | $139.2M | $81.6M | ||
| Q3 25 | $134.2M | $82.0M | ||
| Q2 25 | $122.0M | $81.1M | ||
| Q1 25 | $114.8M | $72.6M | ||
| Q4 24 | $117.5M | $74.0M | ||
| Q3 24 | $119.8M | $78.7M | ||
| Q2 24 | $107.2M | $75.8M |
| Q1 26 | — | $8.1M | ||
| Q4 25 | $49.4M | $10.4M | ||
| Q3 25 | $36.4M | $13.8M | ||
| Q2 25 | $34.2M | $14.0M | ||
| Q1 25 | $26.9M | $8.9M | ||
| Q4 24 | $111.9M | $13.2M | ||
| Q3 24 | $35.9M | $14.3M | ||
| Q2 24 | $32.1M | $11.0M |
| Q1 26 | — | — | ||
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 45.1% | 15.6% | ||
| Q3 25 | 38.0% | 21.3% | ||
| Q2 25 | 35.1% | 21.5% | ||
| Q1 25 | 30.4% | 15.5% | ||
| Q4 24 | 32.6% | 22.7% | ||
| Q3 24 | 33.1% | 22.6% | ||
| Q2 24 | 36.6% | 18.1% |
| Q1 26 | — | 10.2% | ||
| Q4 25 | 35.5% | 12.8% | ||
| Q3 25 | 27.1% | 16.9% | ||
| Q2 25 | 28.1% | 17.2% | ||
| Q1 25 | 23.4% | 12.3% | ||
| Q4 24 | 95.2% | 17.8% | ||
| Q3 24 | 30.0% | 18.2% | ||
| Q2 24 | 29.9% | 14.5% |
| Q1 26 | — | $0.43 | ||
| Q4 25 | $0.20 | $0.55 | ||
| Q3 25 | $0.15 | $0.72 | ||
| Q2 25 | $0.14 | $0.73 | ||
| Q1 25 | $0.11 | $0.47 | ||
| Q4 24 | $0.45 | $0.69 | ||
| Q3 24 | $0.15 | $0.75 | ||
| Q2 24 | $0.13 | $0.57 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $34.2M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $246.6M |
| Total Assets | $624.2M | — |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $34.2M | ||
| Q4 25 | $87.6M | $61.9M | ||
| Q3 25 | $61.4M | $54.7M | ||
| Q2 25 | $90.3M | $48.5M | ||
| Q1 25 | $71.6M | $44.8M | ||
| Q4 24 | $103.1M | $44.1M | ||
| Q3 24 | $86.7M | $63.7M | ||
| Q2 24 | $88.2M | $30.6M |
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $246.6M | ||
| Q4 25 | $477.3M | $251.6M | ||
| Q3 25 | $431.2M | $274.8M | ||
| Q2 25 | $398.3M | $265.6M | ||
| Q1 25 | $373.4M | $260.8M | ||
| Q4 24 | $349.0M | $257.3M | ||
| Q3 24 | $231.9M | $314.4M | ||
| Q2 24 | $188.3M | $301.0M |
| Q1 26 | — | — | ||
| Q4 25 | $624.2M | $1.1B | ||
| Q3 25 | $568.7M | $1.2B | ||
| Q2 25 | $558.4M | $1.2B | ||
| Q1 25 | $510.6M | $1.2B | ||
| Q4 24 | $488.7M | $1.2B | ||
| Q3 24 | $390.6M | $1.3B | ||
| Q2 24 | $376.4M | $1.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | — |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | $11.1M | ||
| Q3 25 | $13.3M | $10.7M | ||
| Q2 25 | $21.1M | $-8.4M | ||
| Q1 25 | $-19.7M | $-1.8M | ||
| Q4 24 | $50.2M | $24.2M | ||
| Q3 24 | $25.0M | $8.4M | ||
| Q2 24 | $45.6M | $-2.6M |
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | $8.9M | ||
| Q3 25 | $-1.1M | $9.8M | ||
| Q2 25 | $18.7M | $-9.5M | ||
| Q1 25 | $-24.4M | $-1.8M | ||
| Q4 24 | $47.5M | $23.4M | ||
| Q3 24 | $24.0M | $8.4M | ||
| Q2 24 | $43.6M | $-2.6M |
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | 10.9% | ||
| Q3 25 | -0.8% | 11.9% | ||
| Q2 25 | 15.3% | -11.7% | ||
| Q1 25 | -21.2% | -2.5% | ||
| Q4 24 | 40.4% | 31.5% | ||
| Q3 24 | 20.0% | 10.7% | ||
| Q2 24 | 40.7% | -3.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 2.6% | ||
| Q3 25 | 10.7% | 1.1% | ||
| Q2 25 | 2.0% | 1.3% | ||
| Q1 25 | 4.1% | 0.0% | ||
| Q4 24 | 2.3% | 1.1% | ||
| Q3 24 | 0.9% | 0.0% | ||
| Q2 24 | 1.9% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.72× | 1.06× | ||
| Q3 25 | 0.36× | 0.77× | ||
| Q2 25 | 0.62× | -0.61× | ||
| Q1 25 | -0.73× | -0.20× | ||
| Q4 24 | 0.45× | 1.83× | ||
| Q3 24 | 0.70× | 0.59× | ||
| Q2 24 | 1.42× | -0.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
AMSF
Segment breakdown not available.
